Protagonist Therapeutics
PTGX
241 hedge funds and large institutions have $2.44B invested in Protagonist Therapeutics in 2024 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 91 increasing their positions, 76 reducing their positions, and 41 closing their positions.
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
20% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 76
1.32% more ownership
Funds ownership: 104.84% → 106.16% (+1.3%)
10% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 41
0% more funds holding
Funds holding: 240 → 241 (+1)
8% less call options, than puts
Call options by funds: $8.73M | Put options by funds: $9.52M
12% less capital invested
Capital invested by funds: $2.78B → $2.44B (-$337M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$43.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$39.7M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$15.4M |
| 4 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$14.9M |
| 5 |
Pictet Asset Management
Carouge,
Switzerland
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$54M |
| 2 |
BlackRock
New York
|
-$14.8M |
| 3 |
JFG
Jefferies Financial Group
New York
|
-$14.2M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$12.9M |
| 5 |
CC
Checkpoint Capital
San Francisco,
California
|
-$10.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
276
Lazard Asset Management
New York
| – | -$121K | -2,697 | Closed |
|
|
GC
277
Globeflex Capital
San Diego,
California
| – | -$118K | -2,627 | Closed |
|
|
QCG
278
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$6.3K | -140 | Closed |
|
|
TWD
279
True Wealth Design
Akron,
Ohio
| – | -$4.32K | -96 | Closed |
|
|
CPA
280
Capital Performance Advisors
Walnut Creek,
California
| – | -$3.56K | -79 | Closed |
|
|
S
281
SignatureFD
Atlanta,
Georgia
| – | -$900 | -20 | Closed |
|
|
MFG
282
Mendota Financial Group
Madison,
Wisconsin
| – | -$270 | -6 | Closed |
|
PTGX Hedge Fund Activity: Q4 2024 in Review
241 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2024, worth a combined $2.44B — down 12% from $2.78B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new PTGX positions and 41 closed out — a net gain of 4 holders — while 91 added to existing stakes and 76 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $43.6M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $54M sold.
- 241 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2024, up from 240 in Q3 2024.
- Funds reported $2.44B of Protagonist Therapeutics stock for Q4 2024, down 12% quarter-over-quarter.
- 45 funds opened new Protagonist Therapeutics positions in Q4 2024 and 41 closed out, a net change of +4 holders.
- The largest Protagonist Therapeutics buyer in Q4 2024 was Deep Track Capital, an estimated $43.6M added.
- The largest Protagonist Therapeutics seller in Q4 2024 was Adage Capital Partners, an estimated $54M sold.
Based on aggregated 13F filings for Q4 2024.